Anthropic has officially released Claude Science, a standalone agentic tool designed to automate complex scientific research. Moving beyond the simple plugins seen in their earlier life sciences release, this product allows researchers to execute high-level instructions across computational biology and drug development. The system even manages code execution on heavy computer clusters while prioritizing reproducibility.

This launch signals a direct challenge to Google DeepMind's dominance in the scientific AI sector. While DeepMind has long led with models like AlphaFold, Anthropic is positioning its agentic capabilities to capture the pharmaceutical market. The company plans to use the tool internally to research treatments for rare, neglected diseases, effectively using its own technology as a testbed.

By targeting molecular biology and genetics, Anthropic aims to secure high-value contracts with well-funded pharmaceutical firms. This strategy provides a clear path toward profitability as the company prepares for a potential IPO. The tool functions as an autonomous researcher, capable of identifying drug candidates for specific genetic conditions like phenylketonuria.